The new and evolving pharmacotherapy of schizophrenia

Psychiatric Clinics of North America

Volumn 26, Issue 1, 2003, Pages 141-163

  Emsley, Robin ^a   Oosthuizen, Piet ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MULTICENTER STUDY; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA;

EID: 0037351073     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(02)00016-3     Document Type: Review

References (88)

1. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001;16:418-23.
2. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multiceneter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
3. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
4. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-67.
5. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
6. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
7. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-46.
8. Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998;140:173-84.
9. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505.
10. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75.
11. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am.J Psychiatry 1997;154:782-91.
12. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995;152:130-4.
13. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72.
14. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999;156:610-6.
15. Puech A, Fleurot O, Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998;98:65-72.
16. Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 1993;34:179-90.
17. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166:712-26.
18. Moller HJ, Bauml J, Ferrero F, Fuger J, Geretsegger C, Kasper S, et al. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. Eur Arch Psychiatry Clin Neurosci 1997;247:291-6.
19. Rabinowitz J, Hornik T, Davidson M. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry 2001;62:343-6.
20. Rabinowitz J, Davidson M. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res 2001;50:89-93.
21. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
22. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
23. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci 2001;55:403-14.
24. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, "Seroquel") and haloperidol in schizophrenia. Psychol Med 2000;30:95-105.
25. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
26. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ. Amisulpride versus haloperidol in treatment of schizophrenic patients - results of a double blind study. Pharmacopsychiatry 1990;23:125-30.
27. Moller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology 1997;132:396-401.
28. Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 2000;15:321-9.
29. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995;91:271-7.
30. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
31. Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology 1998;137:223-32.
32. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
33. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74.
34. Kleiser E, Lehmann E, Knizler E, Wurthmann C, Heinrich K. Randomised, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 2002;15(Suppl 1):45S-51S.
35. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999;88:107-17.
36. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000; CD002306.
37. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
38. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-8.
39. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomised trial. Psychopharmacology 2001;155:128-34.
40. Csernansky JG, Mahmoud T, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:56-8.
41. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9.
42. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-7.
43. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505.
44. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
45. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998;34:61-9.
46. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22.
47. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 1997;11:65-71.
48. Davies A, Adena MA, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: I. meta-analysis of efficacy and safety. Clin Ther 1998;20:58-71.
49. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000; CD000440.
50. Duggan L, Fenton M, Dardennes RM, El Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2000; CD001359.
51. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000; CD000967.
52. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000; CD001945.
53. Lewis R, Bagnall A, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2000; CD001715.
54. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry 1998;59(Suppl):123-9.
55. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal sideeffects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
56. King DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 1998;8:33-42.
57. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995;10:207-13.
58. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a doubleblind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
59. Green MF, Marshall BDJ, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
60. Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, McGurk S, et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry 1998;44:726-32.
61. Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, McGurk SR, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 1999;25:223-32.
62. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-58.
63. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-49.
64. Peuskens J, Van Baelen B, De Smedt C, Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 2000;15:343-9.
65. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-10.
66. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999;46:365-73.
67. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ("seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:121-31.
68. Emsley R, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol (In press).
69. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243-9.
70. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
71. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconomics 1999;15:469-80.
72. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18:567-79.
73. Revicki DA. The new atypical antipsychotics: a review of pharmacoeconomic studies. Expert Opin Pharmacother 2000;1:249-60.
74. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999;8:417-26.
75. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998;18:41-9.
76. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25:721-9.
77. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79-87.
78. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155:499-504.
79. Meltzer HY. Risperidone and clozapine for treatment-resistant schizophrenia. Am J Psychiatry 1999;156:1126-7.
80. Rubin E. Risperidone and clozapine for treatment-resistant schizophrenia. Am J Psychiatry 1999;156:1127.
81. Dunayevich E, Chatterjee A. Risperidone and clozapine for treatment-resistant schizophrenia. Am J Psychiatry 1999;156:1127.
82. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156:294-8.
83. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;158:1305-13.
84. Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374-9.
85. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-20.
86. Kane J, Honigfeld GSJ. Clozapine for the treatment-resistant schizophrenic: a doubleblind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
87. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
88. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26.